These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22920362)

  • 1. Tomographic imaging of the spleen: the role of morphological and metabolic features in differentiating benign from malignant diseases.
    Mainenti PP; Iodice D; Cozzolino I; Segreto S; Capece S; Sica G; Magliulo M; Ciancia G; Pace L; Salvatore M
    Clin Imaging; 2012; 36(5):559-67. PubMed ID: 22920362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
    Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The added value of PET/Ce-CT/DW-MRI fusion in assessment of hepatic focal lesions: PET/Ce-CT/DW-MRI fusion in hepatic focal lesion.
    Salem S; Houseni M; Zidan L; Kandil A
    Nucl Med Biol; 2015 Jul; 42(7):637-42. PubMed ID: 25907467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results.
    Beiderwellen KJ; Poeppel TD; Hartung-Knemeyer V; Buchbender C; Kuehl H; Bockisch A; Lauenstein TC
    Invest Radiol; 2013 May; 48(5):273-9. PubMed ID: 23493121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of incidental focal hypermetabolic uptake in the breast as detected by 18F-FDG PET/CT: clinical significance and differential diagnosis.
    Chae EY; Cha JH; Kim HH; Shin HJ; Kim HJ; Oh HY; Koh YH; Moon DH
    Acta Radiol; 2012 Jun; 53(5):530-5. PubMed ID: 22593124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of CT in Differentiating Malignant Focal Splenic Lesions.
    Jang S; Kim JH; Hur BY; Ahn SJ; Joo I; Kim MJ; Han JK
    Korean J Radiol; 2018; 19(5):930-937. PubMed ID: 30174483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast-enhanced imaging features and differentiation of benign and malignant focal splenic lesions.
    Cao F; Qian W; Ma Y; Wu Y; Zhong J
    Clin Imaging; 2018; 49():58-64. PubMed ID: 29132054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of different contrast medium concentrations and injection protocols on quantitative and clinical assessment of FDG-PET/CT in lung cancer.
    Verburg FA; Kuhl CK; Pietsch H; Palmowski M; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Oct; 82(10):e617-22. PubMed ID: 23880426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body surface area adapted iopromide 300 mg/ml versus 370 mg/ml contrast medium injection protocol: influence on quantitative and clinical assessment in combined PET/CT.
    Verburg FA; Apitzsch J; Lensing C; Kuhl CK; Pietsch H; Mottaghy FM; Behrendt FF
    Eur J Radiol; 2013 Dec; 82(12):2348-52. PubMed ID: 24113432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Texture analysis on (18)F-FDG PET/CT images to differentiate malignant and benign bone and soft-tissue lesions.
    Xu R; Kido S; Suga K; Hirano Y; Tachibana R; Muramatsu K; Chagawa K; Tanaka S
    Ann Nucl Med; 2014 Nov; 28(9):926-35. PubMed ID: 25107363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters.
    Hadiprodjo D; Ryan T; Truong MT; Mercier G; Subramaniam RM
    AJR Am J Roentgenol; 2012 Feb; 198(2):W185-90. PubMed ID: 22268210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of contrast-enhanced FDG-PET/CT in the clinical management of pancreatic cancer: impact on diagnosis, staging, evaluation of treatment response, and detection of recurrence.
    Asagi A; Ohta K; Nasu J; Tanada M; Nadano S; Nishimura R; Teramoto N; Yamamoto K; Inoue T; Iguchi H
    Pancreas; 2013 Jan; 42(1):11-9. PubMed ID: 22699206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidental thyroid uptake on F-18 FDG PET/CT: correlation with ultrasonography and pathology.
    Kang BJ; O JH; Baik JH; Jung SL; Park YH; Chung SK
    Ann Nucl Med; 2009 Oct; 23(8):729-37. PubMed ID: 19768518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colonoscopic Findings in Patients With Incidental Colonic Focal FDG Uptake.
    Keyzer C; Dhaene B; Blocklet D; De Maertelaer V; Goldman S; Gevenois PA
    AJR Am J Roentgenol; 2015 May; 204(5):W586-91. PubMed ID: 25905966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
    Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
    Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT for the characterization of adrenal masses in patients with cancer: qualitative versus quantitative accuracy in 150 consecutive patients.
    Boland GW; Blake MA; Holalkere NS; Hahn PF
    AJR Am J Roentgenol; 2009 Apr; 192(4):956-62. PubMed ID: 19304700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of SUV(max) obtained by 18F-FDG PET/CT in patients with a solitary pancreatic lesion: predicting malignant potential and proliferation.
    Hu SL; Yang ZY; Zhou ZR; Yu XJ; Ping B; Zhang YJ
    Nucl Med Commun; 2013 Jun; 34(6):533-9. PubMed ID: 23503000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of whole-body integrated 18F-FDG PET/MR in comparison to PET/CT for evaluation of malignant bone lesions.
    Eiber M; Takei T; Souvatzoglou M; Mayerhoefer ME; Fürst S; Gaertner FC; Loeffelbein DJ; Rummeny EJ; Ziegler SI; Schwaiger M; Beer AJ
    J Nucl Med; 2014 Feb; 55(2):191-7. PubMed ID: 24309383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.